Viatris (VTRS) Accounts Payables (2019 - 2026)
Viatris' (VTRS) quarterly Accounts Payables came in at $1.7 billion in Q1 2026, down 12.02% year-on-year from $2.0 billion in Q1 2025, and little changed quarter-over-quarter from $1.8 billion in Q4 2025.
Viatris (VTRS) Accounts Payables (2019 - 2026) Analysis & Trends
Viatris' Accounts Payables history runs 8 years deep, the most recent figure standing at $1.7 billion for Q1 2026.
- On a quarterly basis, Accounts Payables fell 12.02% year-over-year to $1.7 billion in Q1 2026; TTM through Mar 2026 was $1.7 billion, a 12.02% decrease from a year earlier, with the FY2025 full-year figure at $1.8 billion, down 5.37% from the prior year.
- Accounts Payables was little changed at $1.7 billion in Q1 2026 per VTRS's latest filing, from $1.8 billion in the prior quarter.
- Across five years, Accounts Payables topped out at $2.2 billion in Q1 2024 and bottomed at $1.3 billion in Q3 2022.
- The 5-year median for Accounts Payables is $1.9 billion (2024), against an average of $1.8 billion.
- Across the five-year window, Accounts Payables decreased 26.61% in 2022 and surged 51.78% in 2023, its largest moves.
- Year by year, Accounts Payables stood at $1.8 billion in 2022, then advanced by 9.71% to $1.9 billion in 2023, then decreased by 4.36% to $1.9 billion in 2024, then retreated by 5.37% to $1.8 billion in 2025, then dropped by 0.27% to $1.7 billion in 2026.
- Per Business Quant, the three latest VTRS Accounts Payables figures stand at $1.7 billion (Q1 2026), $1.8 billion (Q4 2025), and $1.8 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 4.96 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 2.60 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 507.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 3.13 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 498.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 1.67 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.75 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 773.00 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 372.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 58.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.75 Bn |
| Dec 31, 2025 | 1.75 Bn |
| Sep 30, 2025 | 1.79 Bn |
| Jun 30, 2025 | 1.78 Bn |
| Mar 31, 2025 | 1.99 Bn |
| Dec 31, 2024 | 1.85 Bn |
| Sep 30, 2024 | 1.93 Bn |
| Jun 30, 2024 | 1.96 Bn |
| Mar 31, 2024 | 2.20 Bn |
| Dec 31, 2023 | 1.94 Bn |
| Sep 30, 2023 | 1.99 Bn |
| Jun 30, 2023 | 1.96 Bn |
| Mar 31, 2023 | 1.96 Bn |
| Dec 31, 2022 | 1.77 Bn |
| Sep 30, 2022 | 1.31 Bn |
| Jun 30, 2022 | 1.67 Bn |
| Mar 31, 2022 | 1.50 Bn |
| Dec 31, 2021 | 1.66 Bn |
| Sep 30, 2021 | 1.66 Bn |
| Jun 30, 2021 | 1.80 Bn |